Polyomavirus SV40: Model infectious agent of cancer

Current Cancer Research

Volumn 8, Issue , 2012, Pages 377-417

  Butel, Janet S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; MICRORNA; POLIOMYELITIS VACCINE; PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN; VIRUS LARGE T ANTIGEN; VIRUS SMALL T ANTIGEN;

ARTICLE; CARCINOGENESIS; CELL CYCLE; CLINICAL TRIAL (TOPIC); CYTOPLASM; HAMSTER; HUMAN; IMMUNE RESPONSE; NEOPLASM; NONHUMAN; POLIOMYELITIS; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN DOMAIN; VERTICAL TRANSMISSION; VIRUS GENOME;

EID: 84870726548     PISSN: 09400745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0016-5_15     Document Type: Article

References (213)

1. Adams JM, Cory S (1991). Transgenic models of tumor development. Science 254:1161-1167
2. Ahuja D, Sáenz-Robles MT, Pipas JM (2005). SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24:7729-7745
3. Ali SH, Kasper JS, Arai T et al (2004). Cul7/p185/p193 binding to simian virus 40 large T antigen has a role in cellular transformation. J Virol 78:2749-2757
4. Amara K, Trimeche M, Ziadi S et al (2007). Presence of simian virus 40 DNA sequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes. Int J Cancer 121:2693-2702
5. Arrington AS, Butel JS (2001). SV40 and human tumors. In: Khalili K, Stoner GL (eds) Human polyomaviruses: molecular and clinical perspectives. Wiley, New York
6. Arrington AS, Moore MS, Butel JS (2004). SV40-positive brain tumor in scientist with risk of laboratory exposure to the virus. Oncogene 23:2231-2235
7. Baranova N, Carbone M (2010). Simian virus 40 and mesothelioma. In: Khalili K, Jeang K-T (eds) Viral oncology: basic science and clinical applications. Wiley, Hoboken, NJ
8. Bates MP, Jennings SR, Tanaka Y et al (1988). Recognition of simian virus 40 T antigen synthesized during viral lytic cycle in monkey kidney cells expressing mouse H-2Kb-and H-2Db-transfected genes by SV40-specific cytotoxic T lymphocytes leads to the abrogation of virus lytic cycle. Virology 162:197-205
9. Bergsagel DJ, Finegold MJ, Butel JS et al (1992). DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. N Engl J Med 326:988-993
10. Bialasiewicz S, Whiley DM, Lambert SB et al (2009). Detection of BK, JC, WU, or KI polyomaviruses in faecal, urine, blood, cerebrospinal fluid and respiratory samples. J Clin Virol 45:249-254
11. Black PH, Rowe WP (1964). Viral studies of SV40 tumorigenesis in hamsters. J Natl Cancer Inst 32:253-265
12. Bocharov G, Ludewig B, Bertoletti A et al (2004). Underwhelming the immune response: effect of slow virus growth on CD8 +-T-lymphocyte responses. J Virol 78:2247-2254
13. Boyd VAL, Butel JS (1972). Demonstration of infectious deoxyribonucleic acid in transformed cells. I. Recovery of simian virus 40 from yielder and nonyielder transformed cells. J Virol 10:399-409
14. Breau WC, Atwood WJ, Norkin LC (1992). Class I major histocompatibility proteins are an essential component of the simian virus 40 receptor. J Virol 66:2037-2045
15. Bright RK, Kimchi ET, Shearer MH et al (2002). SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients. Cancer Immunol Immunother 50:682-690
16. Brinster RL, Chen HY, Messing A et al (1984). Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 37:367-379
17. Brugge JS, Butel JS (1975). Role of simian virus 40 gene A function in maintenance of transformation. J Virol 15:619-635
18. Butel JS (2000). Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 21:405-426
19. Butel JS (2010). Simian virus 40, human infections, and cancer: emerging concepts and causality considerations. In: Khalili K, Jeang KT (eds) Viral oncology: basic science and clinical applications. Wiley, Hoboken, NJ
20. Butel JS, Lednicky JA (1999). Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 91:119-134
21. Butel JS, Guentzel MJ, Rapp F (1969). Variants of defective simian papovavirus 40 (PARA) characterized by cytoplasmic localization of simian papovavirus 40 tumor antigen. J Virol 4:632-641
22. Butel JS, Tevethia SS, Melnick JL (1972). Oncogenicity and cell transformation by papovavirus SV40: the role of the viral genome. Adv Cancer Res 15:1-55
23. Butel JS, Arrington AS, Wong C et al (1999). Molecular evidence of simian virus 40 infections in children. J Infect Dis 180:884-887
24. Butel JS, Wong C, Vilchez RA et al (2003). Detection of antibodies to polyomavirus SV40 in two central European countries. Cent Eur J Public Health 11:3-8
25. Cabasso VJ, Jervis GA, Moyer AW et al (1960). Cumulative testing experience with consecutive lots of oral poliomyelitis vaccine. Br Med J 1(5170):373-387
26. Carbone M, Lewis AM Jr, Matthews BJ et al (1989). Characterization of hamster tumors induced by simian virus 40 small t deletion mutants as true histiocytic lymphomas. Cancer Res 49:1565-1571
27. Carbone M, Stach R, Di Resta I et al (1998). Simian virus 40 oncogenesis in hamsters. Dev Biol Stand 94:273-279
28. Chen J, Van Dyke T (1991). Uniform cell-autonomous tumorigenesis of the choroid plexus by papovavirus large T antigens. Mol Cell Biol 11:5968-5976
29. Chen J, Tobin GJ, Pipas JM et al (1992). T-antigen mutant activities in vivo: roles of p53 and pRB binding in tumorigenesis of the choroid plexus. Oncogene 7:1167-1175
30. Chumakov MP (1961). Oral live poliovirus vaccine. Papers Presented at the fourth scientific conference of the Institute of Poliomyelitis and Virus Encephalitis and the international symposium on live poliovirus vaccine, May 17-20, 1960, Moscow. Academy of Medical Sciences of the USSR, Moscow
31. Cicala C, Pompetti F, Carbone M (1993). SV40 induces mesotheliomas in hamsters. Am J Pathol 142:1524-1533
32. Cole CN, Crawford LV, Berg P (1979). Simian virus 40 mutants with deletions at the 3' end of the early region are defective in adenovirus helper function. J Virol 30:683-691
33. Coleman S, Gibbs A, Butchart E et al (2008). SV40 large T antigen-specific human T cell memory responses. J Med Virol 80:1497-1504
34. Comar M, Rizzardi C, de Zotti R et al (2007). SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma. Cancer Res 67:8456-8459
35. Comar M, Zanotta N, Bovenzi M et al (2010). JCV/BKV and SV40 viral load in lymphoid tissues of young immunocompetent children from an area of north-east Italy. J Med Virol 82:1236-1240
36. Cotsiki M, Lock RL, Cheng Y et al (2004). Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci USA 101:947-952
37. Cristaudo A, Foddis R, Vivaldi A et al (2005). SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 65:3049-3052
38. Cutrone R, Lednicky J, Dunn G et al (2005). Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res 65:10273-10279
39. Dang X, Axthelm MK, Letvin NL et al (2005). Rearrangement of simian virus 40 regulatory region is not required for induction of progressive multifocal leukoencephalopathy in immunosuppressed rhesus monkeys. J Virol 79:1361-1366
40. Dang-Tan T, Mahmud SM, Puntoni R et al (2004). Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 23:6535-6540
41. David H, Mendoza S, Konishi T et al (2001). Simian virus 40 is present in human lymphomas and normal blood. Cancer Lett 162:57-64
42. DeCaprio JA (2009). How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40. Virology 384:274-284
43. DeCaprio JA, Ludlow JW, Figge J et al (1988). SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-283
44. Deckhut AM, Lippolis JD, Tevethia SS (1992). Comparative analysis of core amino acid residues of H-2D b-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen. J Virol 66:440-447
45. Deeb KK, Michalowska AM, Yoon CY et al (2007). Identification of an integrated SV40 T/tantigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 67:8065-8080
46. Diamandopoulos GT (1973). Induction of lymphocytic leukemia, lymphosarcoma, reticulum cell sarcoma, and osteogenic sarcoma in the Syrian golden hamster by oncogenic DNA simian virus 40. J Natl Cancer Inst 50:1347-1365
47. Digweed M, Demuth I, Rothe S et al (2002). SV40 large T-antigen disturbs the formation of nuclear DNA-repair foci containing MRE11. Oncogene 21:4873-4878
48. Donehower LA, Harvey M, Slagle BL et al (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221
49. Eddy BE, Borman GS, Berkeley WH et al (1961). Tumors induced in hamsters by injection of rhesus monkey kidney cell extracts. Proc Soc Exp Biol Med 107:191-197
50. Eddy BE, Borman GS, Grubbs GE et al (1962). Identification of the oncogenic substance in rhesus monkey cell cultures as simian virus 40. Virology 17:65-75
51. Ewald D, Li M, Efrat S et al (1996). Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 273:1384-1386
52. Fanning E, Zhao K (2009). SV40 DNA replication: from the A gene to a nanomachine. Virology 384:352-359
53. Feinstone SM, Gust ID (2002). Hepatitis A virus. In: Richman DD, Whitley RJ, Hayden FG (eds) Clinical virology, 2nd edn. ASM, Washington, DC
54. Forsman ZH, Lednicky JA, Fox GE et al (2004). Phylogenetic analysis of polyomavirus simian virus 40 from monkeys and humans reveals genetic variation. J Virol 78:9306-9316
55. Förster I, Hirose R, Arbeit JM et al (1995). Limited capacity for tolerization of CD4 + T cells specific for a pancreatic b cell neo-antigen. Immunity 2:573-585
56. Fraumeni JF Jr, Ederer F, Miller RW (1963). An evaluation of the carcinogenicity of simian virus 40 in man. J Am Med Assoc 185:713-718
57. Gerber P (1964). Virogenic hamster tumor cells: induction of virus synthesis. Science 145:833
58. Girardi AJ, Sweet BH, Slotnick VB et al (1962). Development of tumors in hamsters inoculated in the neonatal period with vacuolating virus, SV 40. Proc Soc Exp Biol Med 109:649-660
59. Gjoerup O, Chang Y (2010). Update on human polyomaviruses and cancer. Adv Cancer Res 106:1-51
60. Graham DY (1991). Helicobacter pylori in human populations: the present and predictions of the future based on the epidemiology of polio. In: Menge H et al (eds) Helicobacter pylori 1990. Proceedings of the second international symposium on Helicobacter pylori, Bad Nauheim, August 25-26, 1989. Springer, Berlin
61. Hahn WC, Dessain SK, Brooks MW et al (2002). Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 22:2111-2123
62. Hanahan D (1989). Transgenic mice as probes into complex systems. Science 246:1265-1275
63. Heinsohn S, Szendroi M, Bielack S et al (2009). Evaluation of SV40 in osteosarcoma and healthy population: a Hungarian-German study. Oncol Rep 21:289-297
64. Hilleman MR (1998). Discovery of simian virus 40 (SV 40) and its relationship to poliomyelitis virus vaccines. Dev Biol Stand 94:183-190
65. Huebner RJ, Chanock RM, Rubin BA et al (1964). Induction by adenovirus type 7 of tumors in hamsters having the antigenic characteristics of SV40 virus. Proc Natl Acad Sci USA 52:1333-1340
66. Ilyinskii PO, Daniel MD, Horvath CJ et al (1992). Genetic analysis of simian virus 40 from brains and kidneys of macaque monkeys. J Virol 66:6353-6360
67. Imperiale MJ, Major EO (2007). Polyomaviruses. In: Knipe DM et al (eds) Fields virology, 5th edn. Lippincott Williams & Wilkins, Philadelphia
68. Javier RT, Butel JS (2008). The history of tumor virology. Cancer Res 68:7693-7706
69. Kalderon D, Richardson WD, Markham AF et al (1984). Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature 311:33-38
70. Kean JM, Rao S, Wang M et al (2009). Seroepidemiology of human polyomaviruses. PLoS Pathog 5:e1000363
71. Khalili K, Sariyer IK, Safak M (2008). Small tumor antigen of polyomaviruses: role in viral life cycle and cell transformation. J Cell Physiol 215:309-319
72. Kierstead TD, Tevethia MJ (1993). Association of p53 binding and immortalization of primary C57BL/6 mouse embryo fibroblasts by using simian virus 40 T-antigen mutants bearing internal overlapping deletion mutations. J Virol 67:1817-1829
73. Kim B-H, Song J-H, Jeon Y-C et al (2009). Spontaneous immortalization of oligodendroglial cells derived from an SV40 T antigen-positive human glioblastoma multiforme. Cancer Lett 283:212-221
74. Kirschstein RL, Gerber P (1962). Ependymomas produced after intracerebral inoculation of SV40 into newborn hamsters. Nature 195:299-300
75. Koprowski H (2006). First decade (1950-1960) of studies and trials with the polio vaccine. Biologicals 34:81-86
76. Kroczynska B, Cutrone R, Bocchetta M et al (2006). Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 103:14128-14133
77. Lane DP, Crawford LV (1979). T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263
78. Lanford RE, Butel JS (1980). Inhibition of nuclear migration of wild-type SV40 tumor antigen by a transport-defective mutant of SV40-adenovirus 7 hybrid virus. Virology 105:303-313
79. Lanford RE, Butel JS (1984). Construction and characterization of an SV40 mutant defective in nuclear transport of T antigen. Cell 37:801-813
80. Lanford RE, Hyland JK, Baserga R et al (1985a). Induction of cellular DNA synthesis by a simian virus 40 mutant defective in nuclear transport of T antigen. Mol Cell Biol 5:1531-1533
81. Lanford RE, Wong C, Butel JS (1985b). Differential ability of a T-antigen transport-defective mutant of simian virus 40 to transform primary and established rodent cells. Mol Cell Biol 5:1043-1050
82. Lanford RE, Jacob JR, Butel JS (1986). Genomic organization of the simian virus 40-adenovirus 7 hybrid virus, PARA(cT), that encodes a nuclear transport defective simian virus 40 T antigen. Virology 155:271-276
83. Lapin BA, Chikobava MG (2009). Detection of SV40 in blood samples from healthy subjects in the Russian Federation by RT-PCR [Article in Russian]. Vestn Ross Akad Med Nauk 4:7-10
84. Lednicky JA, Butel JS (1997). Tissue culture adaptation of natural isolates of simian virus 40: changes occur in viral regulatory region but not in carboxy-terminal domain of large T-antigen. J Gen Virol 78:1697-1705
85. Lednicky JA, Butel JS (1999). Polyomaviruses and human tumors: a brief review of current concepts and interpretations. Frontiers Biosci 4:153-164
86. Lednicky JA, Butel JS (2001). Simian virus 40 regulatory region structural diversity and the association of viral archetypal regulatory regions with human brain tumors. Semin Cancer Biol 11:39-47
87. Lednicky JA, Butel JS (2011). Simian virus 40. In: Tidona C (ed) Springer index of viruses, 2nd edn
88. Lednicky JA, Garcea RL, Bergsagel DJ et al (1995a). Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors. Virology 212:710-717
89. Lednicky JA, Wong C, Butel JS (1995b). Artificial modification of the viral regulatory region improves tissue culture growth of SV40 strain 776. Virus Res 35:143-153
90. Lednicky JA, Arrington AS, Stewart AR et al (1998). Natural isolates of simian virus 40 from immunocompromised monkeys display extensive genetic heterogeneity: new implications for polyomavirus disease. J Virol 72:3980-3990
91. Levine AJ (2009). The common mechanisms of transformation by the small DNA tumor viruses: the inactivation of tumor suppressor gene products: p53. Virology 384:285-293
92. Lewis AM Jr (1998). SV40 in adenovirus vaccines and adenovirus-SV40 recombinants. Dev Biol Stand 94:207-216
93. Li RM, Branton MH, Tanawattanacharoen S et al (2002a). Molecular identification of SV40 infection in human subjects and possible association with kidney disease. J Am Soc Nephrol 13:2320-2330
94. Li RM, Mannon RB, Kleiner D et al (2002b). BK virus and SV40 co-infection in polyomavirus nephropathy. Transplantation 74:1497-1504
95. Lill NL, Tevethia MJ, Hendrickson WG et al (1992). Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes. J Exp Med 176:449-457
96. Linzer DI, Levine AJ (1979). Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52
97. Lippolis JD, Mylin LM, Simmons DT et al (1995). Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen. J Virol 69:3134-3146
98. Lundstig A, Eliasson L, Lehtinen M et al (2005). Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. J Gen Virol 86:1703-1708
99. Markovics JA, Carroll PA, Robles MTS et al (2005). Intestinal dysplasia induced by simian virus 40 T antigen is independent of p53. J Virol 79:7492-7502
100. Martin RG, Chou JY (1975). Simian virus 40 functions required for the establishment and maintenance of malignant transformation. J Virol 15:599-612
101. Martini F, Iaccheri L, Lazzarin L et al (1996). SV40 early region and large T antigen in human brain tumors, peripheral blood cells, and sperm fluids from healthy individuals. Cancer Res 56:4820-4825
102. Martini F, Lazzarin L, Iaccheri L et al (2002). Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. Cancer 94:1037-1048
103. Martini F, Corallini A, Balatti V et al (2007). Simian virus 40 in humans. Infect Agent Cancer 2:e13
104. McNees AL, Butel JS (2008). Simian virus 40. In: Mahy BWJ, van Regenmortel MHV (eds) Encyclopedia of virology, 3rd edn. Elsevier, Oxford
105. McNees AL, Vilchez RA, Heard TC et al (2009). SV40 lymphomagenesis in Syrian golden hamsters. Virology 384:114-124
106. Melnick JL (1960). Houston field trial of live poliovirus vaccine. Med Rec Ann 53:85-86
107. Melnick JL (1985). Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields BN et al (eds) Virology. Raven, New York
108. Melnick JL, Stinebaugh S (1962). Excretion of vacuolating SV-40 virus (papova virus group) after ingestion as a contaminant of oral poliovaccine. Proc Soc Exp Biol Med 109:965-968
109. Meneses A, Lopez-Terrada D, Zanwar P et al (2005). Lymphoproliferative disorders in Costa Rica and simian virus 40. Haematologica 90:1635-1642
110. Milstone A, Vilchez RA, Geiger X et al (2004). Polyomavirus simian virus 40 infection associated with nephropathy in a lung-transplant recipient. Transplantation 77:1019-1024
111. Minor P, Pipkin P, Jarzebek Z et al (2003). Studies of neutralising antibodies to SV40 in human sera. J Med Virol 70:490-495
112. Mylin LM, Deckhut AM, Bonneau RH et al (1995). Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2K b-restricted determinant in simian virus 40 tumor antigen. Virology 208:159-172
113. Mylin LM, Schell TD, Epler M et al (2007). Diversity of escape variant mutations in simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology 364:155-168
114. Nakatsuka S-I, Liu A, Dong Z et al (2003). Simian virus 40 sequences in malignant lymphomas in Japan. Cancer Res 63:7606-7608
115. Neu U, Woellner K, Gauglitz G et al (2008). Structural basis of GM1 ganglioside recognition by simian virus 40. Proc Natl Acad Sci USA 105:5219-5224
116. Newman JS, Baskin GB, Frisque RJ (1998). Identification of SV40 in brain, kidney and urine of healthy and SIV-infected rhesus monkeys. J Neurovirol 4:394-406
117. Newmaster RS, Mylin LM, Fu TM et al (1998). Role of a subdominant H-2K d-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection. Virology 244:427-441
118. Noonan CA, Brugge JS, Butel JS (1976). Characterization of simian cells tranformed by temperature-sensitive mutants of simian virus 40. J Virol 18:1106-1119
119. Nurgalieva ZZ, Malaty HM, Graham DY et al (2002). Helicobacter pylori infection in Kazakhstan: effect of water source and household hygiene. Am J Trop Med Hyg 67:201-206
120. Nurgalieva ZZ, Wong C, Zhangabylov AK et al (2005). Polyomavirus SV40 infections in Kazakhstan. J Infect 50:142-148
121. Otahal P, Schell TD, Hutchinson SC et al (2006). Early immunization induces persistent tumor-infiltrating CD8 + T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J Immunol 177:3089-3099
122. Pagano JS, Blaser M, Buendia MA et al (2004). Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 14:453-471
123. Pan American Sanitary Bureau (1959). First international conference on live poliovirus vaccines, Washington, DC, 22-26 June 1959. Papers presented and discussions held. Pan American Sanitary Bureau, Scientific Publication No. 44, Washington, DC
124. Pan American Sanitary Bureau (1960). Second international conference on live poliovirus vaccines, Washington, DC, 6-10 June 1960. Papers presented and discussions held. Pan American Sanitary Bureau, Scientific Publication No. 50, Washington, DC
125. Pancaldi C, Balatti V, Guaschino R et al (2009). Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. J Infect 58:53-60
126. Paracchini V, Garte S, Pedotti P et al (2005). Molecular identification of simian virus 40 infection in healthy Italian subjects by birth cohort. Mol Med 11:48-51
127. Paracchini V, Garte S, Pedotti P et al (2006). Review of prevalence of Simian Virus 40 (SV40) genomic infection in healthy subjects. Mutat Res 612:77-83
128. Patel NC, Vilchez RA, Killen DE et al (2008). Detection of polyomavirus SV40 in tonsils from immunocompetent children. J Clin Virol 43:66-72
129. Patel NC, Halvorson SJ, Sroller V et al (2009). Viral regulatory region effects on vertical transmission of polyomavirus SV40 in hamsters. Virology 386:94-101
130. Paul JR (1971). A history of poliomyelitis. Yale University Press, New Haven
131. Pinkert CA, Brinster RL, Palmiter RD et al (1987). Tumorigenesis in transgenic mice by a nuclear transport-defective SV40 large T-antigen gene. Virology 160:169-175
132. Pipas JM (1985). Mutations near the carboxyl terminus of the simian virus 40 large tumor antigen alter viral host range. J Virol 54:569-575
133. Pipas JM (2009). SV40: cell transformation and tumorigenesis. Virology 384:294-303
134. Plotkin SA (2001). CHAT oral polio vaccine was not the source of human immunodeficiency virus type 1 group M for humans. Clin Infect Dis 32:1068-1084
135. Poulin DL, DeCaprio JA (2006). Is there a role for SV40 in human cancer? J Clin Oncol 24:4356-4365
136. Poulin DL, Kung AL, DeCaprio JA (2004). p53 targets simian virus 40 large T antigen for acetylation by CBP. J Virol 78:8245-8253
137. Procopio A, Strizzi L, Vianale G et al (2000). Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer 29:173-179
138. Ramos-Alvarez M, Gomez-Santos F (1961). Laboratory and field studies in Mexico with Sabin's live poliovirus vaccines. In: Poliomyelitis. Papers and discussions presented at the fifth international poliomyelitis conference, Copenhagen, July 26-28, 1960. Lippincott, Philadelphia
139. Rapp F, Melnick JL, Butel JS et al (1964). The incorporation of SV40 genetic material into adenovirus 7 as measured by intranuclear synthesis of SV40 tumor antigen. Proc Natl Acad Sci USA 52:1348-1352
140. Rapp F, Tevethia SS, Rawls WE et al (1967). Production of antibodies to papovavirus SV40 tumor antigen in African green monkeys. Proc Soc Exp Biol Med 125:794-798
141. Rathi AV, Pipas JM (2010). Oncogenic transformation by polyomavirus large T antigen. In: Khalili K, Jeang KT (eds) Viral oncology: basic science and clinical applications. Wiley, Hoboken, NJ
142. Rathi AV, Sáenz Robles MT, Cantalupo PG et al (2009). Simian virus 40 T-antigen-mediated gene regulation in enterocytes is controlled primarily by the Rb-E2F pathway. J Virol 83:9521-9531
143. Robinson C, van Bruggen I, Segal A et al (2006). A novel SV40 TAg transgenic model of asbestosinduced mesothelioma: malignant transformation is dose dependent. Cancer Res 66:10786-10794
144. Rochford R, Villarreal LP (1991). Polyomavirus DNA replication in the pancreas and in a transformed pancreas cell line has distinct enhancer requirements. J Virol 65:2108-2112
145. Rollison DEM (2006). Epidemiologic studies of polyomaviruses and cancer: previous findings, methodologic challenges and future directions. In: Ahsan N (ed) Polyomaviruses and human diseases. Landes Biosciences, Georgetown, TX
146. Rollison DEM, Shah KV (2001). The epidemiology of SV40 infection due to contaminated polio vaccines: relation of the virus to human cancer. In: Khalili K, Stoner GL (eds) Human polyomaviruses: molecular and clinical perspectives. Wiley-Liss, Inc., New York
147. Rollison DEM, Page WF, Crawford H et al (2004). Case-control study of cancer among US Army veterans exposed to simian virus 40-contaminated adenovirus vaccine. Am J Epidemiol 160:317-324
148. Rowe WP, Baum SG (1964). Evidence for a possible genetic hybrid between adenovirus type 7 and SV40 viruses. Proc Natl Acad Sci USA 52:1340-1347
149. Sabin AB (1985). Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 151:420-436
150. Sabin AB (1991). Perspectives on rapid elimination and ultimate global eradication of paralytic poliomyelitis caused by polioviruses. Eur J Epidemiol 7:95-120
151. Sabin AB, Koch MA (1963). Behavior of noninfectious SV 40 viral genome in hamster tumor cells: induction of synthesis of infectious virus. Proc Natl Acad Sci USA 50:407-417
152. Sabin AB, Michaels RH, Spigland I et al (1961). Community-wide use of oral poliovirus vaccine. Effectiveness of the Cincinnati program. Am J Dis Child 101:546-567
153. Sáenz Robles MT, Pipas JM (2009). T antigen transgenic mouse models. Semin Cancer Biol 19:229-235
154. Sáenz-Robles MT, Symonds H, Chen J et al (1994). Induction versus progression of brain tumor development: differential functions for the pRB-and p53-targeting domains of simian virus 40 T antigen. Mol Cell Biol 14:2686-2698
155. Sáenz-Robles MT, Sullivan CS, Pipas JM (2001). Transforming functions of simian virus 40. Oncogene 20:7899-7907
156. Sáenz-Robles MT, Markovics JA, Chong JL et al (2007). Intestinal hyperplasia induced by simian virus 40 large tumor antigen requires E2F2. J Virol 81:13191-13199
157. Schell TD, Tevethia SS (2001). Cytotoxic T lymphocytes in SV40 infections. Methods Mol Biol 165:243-256
158. Schell TD, Lippolis JD, Tevethia SS (2001). Cytotoxic T lymphocytes from HLA-A2.1 transgenic mice define a potential human epitope from simian virus 40 large T antigen. Cancer Res 61:873-879
159. Sepulveda AR, Finegold MJ, Smith B et al (1989). Development of a transgenic mouse system for the analysis of stages in liver carcinogenesis using tissue-specific expression of SV40 large T-antigen controlled by regulatory elements of the human a-1-antitrypsin gene. Cancer Res 49:6108-6117
160. Shadan FF, Villarreal LP (1993). Coevolution of persistently infecting small DNA viruses and their hosts linked to host-interactive regulatory domains. Proc Natl Acad Sci USA 90:4117-4121
161. Shah KV (2000). Does SV40 infection contribute to the development of human cancers? Rev Med Virol 10:31-43
162. Shah K, Nathanson N (1976). Human exposure to SV40: review and comment. Am J Epidemiol 103:1-12
163. Shah KV, Galloway DA, Knowles WA et al (2004). Simian virus 40 (SV40) and human cancer: a review of the serological data. Rev Med Virol 14:231-239
164. Shivapurkar N, Takahashi T, Reddy J et al (2004). Presence of simian virus 40 DNA sequences in human lymphoid and hematopoietic malignancies and their relationship to aberrant promoter methylation of multiple genes. Cancer Res 64:3757-3760
165. Spence SL, Pipas JM (1994). SV40 large T antigen functions at two distinct steps in virion assembly. Virology 204:200-209
166. Srinivasan A, McClellan AJ, Vartikar J et al (1997). The amino-terminal transforming region of simian virus 40 large T and small t antigens functions as a J domain. Mol Cell Biol 17:4761-4773
167. Sroller V, Vilchez RA, Stewart AR et al (2008). Influence of the viral regulatory region on tumor induction by simian virus 40 in hamsters. J Virol 82:871-879
168. Stacy T, Chamberlain M, Cole CN (1989). Simian virus 40 host range/helper function mutations cause multiple defects in viral late gene expression. J Virol 63:5208-5215
169. Stewart AR, Lednicky JA, Benzick US et al (1996). Identification of a variable region at the carboxy terminus of SV40 large T-antigen. Virology 221:355-361
170. Stewart AR, Lednicky JA, Butel JS (1998). Sequence analyses of human tumor-associated SV40 DNAs and SV40 viral isolates from monkeys and humans. J Neurovirol 4:182-193
171. Stratton K, Almario DA, McCormick MC (2003). Immunization safety review: SV40 contamination of polio vaccine and cancer. The National Academies Press, Washington, DC
172. Strickler HD, Rosenberg PS, Devesa SS et al (1998). Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. J Am Med Assoc 279:292-295
173. Sullivan CS, Pipas JM (2002). T antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesis. Microbiol Mol Biol Rev 66:179-202
174. Sullivan CS, Cantalupo P, Pipas JM (2000). The molecular chaperone activity of simian virus 40 large T antigen is required to disrupt Rb-E2F family complexes by an ATP-dependent mechanism. Mol Cell Biol 20:6233-6243
175. Sullivan CS, Grundhoff AT, Tevethia S et al (2005). SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nature 435:682-686
176. Suzuki M, Toyooka S, Shivapurkar N et al (2005). Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene 24:1302-1308
177. Sweet BH, Hilleman MR (1960). The vacuolating virus, S.V. 40. Proc Soc Exp Biol Med 105:420-427
178. Symonds HS, McCarthy SA, Chen J et al (1993). Use of transgenic mice reveals cell-specific transformation by a simian virus 40 T-antigen amino-terminal mutant. Mol Cell Biol 13:3255-3265
179. Symonds H, Krall L, Remington L et al (1994). p53-Dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711
180. Tatum AM, Mylin LM, Bender SJ et al (2008). CD8 + T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. J Immunol 181:4406-4417
181. Tegtmeyer P (1975). Function of simian virus 40 gene A in transforming infection. J Virol 15:613-618
182. Tevethia SS (1970). Immune response of rabbits to purified papovavirus SV40. J Immunol 104:72-78
183. Tevethia SS (1990). Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes. Mol Biol Med 7:83-96
184. Tevethia SS, Schell TD (2001). The immune response to SV40, JCV, and BKV. In: Khalili K, Stoner GL (eds) Human polyomaviruses: molecular and clinical perspectives. Wiley-Liss, Inc., New York
185. Tevethia MJ, Bonneau RH, Griffith JW et al (1997). A simian virus 40 large T-antigen segment containing amino acids 1 to 127 and expressed under the control of the rat elastase-1 promoter produces pancreatic acinar carcinomas in transgenic mice. J Virol 71:8157-8166
186. Tevethia SS, Mylin L, Newmaster R et al (1998). Cytotoxic T lymphocyte recognition sequences as markers for distinguishing among tumour antigens encoded by SV40, BKV and JCV. Dev Biol Stand 94:329-339
187. Thomas LD, Milstone AP, Vilchez RA et al (2009). Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation. Transplantation 88:360-366
188. Toracchio S, Kozinetz CA, Killen DE et al (2009). Variable frequency of polyomavirus SV40 and herpesvirus EBV in lymphomas from two different urban population groups in Houston, TX. J Clin Virol 46:154-160
189. Tornow J, Polvino-Bodnar M, Santangelo G et al (1985). Two separable functional domains of simian virus 40 large T antigen: carboxyl-terminal region of simian virus 40 large T antigen is required for efficient capsid protein synthesis. J Virol 53:415-424
190. Tsai B, Gilbert JM, Stehle T et al (2003). Gangliosides are receptors for murine polyoma virus and SV40. EMBO J 22:4346-4355
191. Van Dyke TA (1994). Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. Semin Cancer Biol 5:47-60
192. Vanchiere JA, Nicome RK, Greer JM et al (2005a). Frequent detection of polyomaviruses in stool samples from hospitalized children. J Infect Dis 192:658-664
193. Vanchiere JA, White ZS, Butel JS (2005b). Detection of BK virus and simian virus 40 in the urine of healthy children. J Med Virol 75:447-454
194. Vanchiere JA, Abudayyeh S, Copeland CM et al (2009). Polyomavirus shedding in the stool of healthy adults. J Clin Microbiol 47:2388-2391
195. Velders MP, Macedo MF, Provenzano M et al (2001). Human T cell responses to endogenously presented HLA-A*0201 restricted peptides of simian virus 40 large T antigen. J Cell Biochem 82:155-162
196. Vilchez RA, Butel JS (2004). Emergent human pathogen simian virus 40 and its role in cancer. Clin Microbiol Rev 17:495-508
197. Vilchez RA, Kozinetz CA, Butel JS (2003). Conventional epidemiology and the link between SV40 and human cancers. Lancet Oncol 4:188-191
198. Vilchez RA, Brayton CF, Wong C et al (2004). Differential ability of two simian virus 40 strains to induce malignancies in weanling hamsters. Virology 330:168-177
199. Vilchez RA, Lopez-Terrada D, Middleton JR et al (2005). Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma. Virology 342:38-46
200. Vonka V, Zavadova H, Kutinova L et al (1967). Development of antibodies against viral and tumor antigens of papovavirus SV40 in monkeys. Proc Soc Exp Biol Med 125:790-794
201. Walton M, Melnick JL (1955). Poliomyelitis antibodies in two differing socioeconomic groups within the same city. Yale J Biol Med 27:350-370
202. Welcker M, Clurman BE (2005). The SV40 large T antigen contains a decoy phosphodegron that mediates its interactions with Fbw7/hCdc4. J Biol Chem 280:7654-7658
203. White MK, Khalili K (2004). Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis. Virology 324:1-16
204. Whyte P, Buchkovich KJ, Horowitz JM et al (1988). Association between an oncogene and an antioncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334:124-129
205. Wong ASY, Cheng VCC, Yuen K-Y et al (2009). High frequency of polyoma BK virus shedding in the gastrointestinal tract after hematopoietic stem cell transplantation: a prospective and quantitative analysis. Bone Marrow Transplant 43:43-47
206. Wu X, Avni D, Chiba T et al (2004). SV40 T antigen interacts with Nbs1 to disrupt DNA replication control. Genes Dev 18:1305-1316
207. Yamamoto H, Nakayama T, Murakami H et al (2000). High incidence of SV40-like sequences detection in tumour and peripheral blood cells of Japanese osteosarcoma patients. Br J Cancer 82:1677-1681
208. Yaniv M (2009). Small DNA tumour viruses and their contributions to our understanding of transcription control. Virology 384:369-374
209. Yogo Y, Sugimoto C (2001). The archetype concept and regulatory region rearrangement. In: Khalili K, Stoner GL (eds) Human polyomaviruses: molecular and clinical perspectives. Wiley-Liss, Inc., New York
210. Yorty JL, Tevethia SS, Schell TD (2008). Rapid accumulation of adoptively transferred CD8 + T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. Cancer Immunol Immunother 57:883-895
211. Zekri AN, Bahnassy AA, Mohamed WS et al (2007). Evaluation of simian virus-40 as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma. Pathol Int 57:493-501
212. Zhen HN, Zhang X, Bu XY et al (1999). Expression of the simian virus 40 large tumor antigen (Tag) and formation of Tag-p53 and Tag-pRb complexes in human brain tumors. Cancer 86:2124-2132
213. Zheng X, Gao JX, Zhang H et al (2002). Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J Immunol 169:4761-4769